OBI Pharma to Showcase Research Achievements and Cutting Edge ADC Platform Technology Frequent Speaking Engagements at Prestigious International Conferences

OBI Pharma and Fu Jen Catholic University Sign Industry-Academia Collaboration MOU Advancing Biotechnology Innovation and Developing Young Talent

OBI volunteers at a breast cancer patient event Showcasing our commitment to patients and to new drug development.

Ascentawits Pharma announced the interim analysis results of the AST-3424 Phase II clinical efficacy and safety study in advanced HCC at the 2024 CSCO conference

OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards

The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs

OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

OBI Pharma: An Exciting Launching Pad for Young Scientists

OBI’s Proprietary ADC Platform GlycOBI® Seeks Collaborative Partnerships for Development

Vision: OBI Presents a Five-Year Strategic Plan